EE200200439A - Tsentraalsete kannabinoidiretseptorite antagonisti kasutamine ravimtoodete valmistamiseks, aitamaksloobuda tubakatarbimisest - Google Patents

Tsentraalsete kannabinoidiretseptorite antagonisti kasutamine ravimtoodete valmistamiseks, aitamaksloobuda tubakatarbimisest

Info

Publication number
EE200200439A
EE200200439A EEP200200439A EEP200200439A EE200200439A EE 200200439 A EE200200439 A EE 200200439A EE P200200439 A EEP200200439 A EE P200200439A EE P200200439 A EEP200200439 A EE P200200439A EE 200200439 A EE200200439 A EE 200200439A
Authority
EE
Estonia
Prior art keywords
production
receptor antagonist
pharmaceutical products
cannabinoid receptor
central cannabinoid
Prior art date
Application number
EEP200200439A
Other languages
English (en)
Inventor
Charles Blanchard Jean
Menard Fran�ois
Original Assignee
Sanofi-Synthlabo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi-Synthlabo filed Critical Sanofi-Synthlabo
Publication of EE200200439A publication Critical patent/EE200200439A/et
Publication of EE04836B1 publication Critical patent/EE04836B1/et

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
EEP200200439A 2000-02-09 2001-02-07 N-piperidino-5-(4-klorofenüül)-1-(2,4-diklorofenüül)-4-metüülpürasool-3-karboksamii di kasutamine ravimtoodete valmistamiseks, aitamaks loobuda tubakatarbimisest EE04836B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0001682A FR2804604B1 (fr) 2000-02-09 2000-02-09 Utilisation d'un antagoniste des recepteurs aux cannabinoides centraux pour la preparation de medicaments utiles pour faciliter l'arret de la consommation de tabac
PCT/FR2001/000356 WO2001058450A2 (fr) 2000-02-09 2001-02-07 Utilisation d'un antagoniste des recepteurs aux cannabinoides centraux pour la preparation de medicaments utiles pour faciliter l'arret de la consommation de tabac

Publications (2)

Publication Number Publication Date
EE200200439A true EE200200439A (et) 2003-12-15
EE04836B1 EE04836B1 (et) 2007-06-15

Family

ID=8846875

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200200439A EE04836B1 (et) 2000-02-09 2001-02-07 N-piperidino-5-(4-klorofenüül)-1-(2,4-diklorofenüül)-4-metüülpürasool-3-karboksamii di kasutamine ravimtoodete valmistamiseks, aitamaks loobuda tubakatarbimisest

Country Status (33)

Country Link
US (2) US6930122B2 (et)
EP (1) EP1257275B1 (et)
JP (2) JP2003522145A (et)
CN (1) CN1250220C (et)
AR (1) AR028505A1 (et)
AT (1) ATE292467T1 (et)
AU (1) AU781827B2 (et)
BG (2) BG110386A (et)
BR (1) BR0108126A (et)
CA (1) CA2397262C (et)
CZ (1) CZ296685B6 (et)
DE (1) DE60109903T2 (et)
DK (1) DK1257275T3 (et)
EE (1) EE04836B1 (et)
ES (1) ES2240416T3 (et)
FR (1) FR2804604B1 (et)
HK (1) HK1051140A1 (et)
HU (1) HU225328B1 (et)
IL (1) IL150710A0 (et)
IS (1) IS6450A (et)
MX (1) MXPA02007766A (et)
NO (1) NO324521B1 (et)
NZ (1) NZ519924A (et)
PL (1) PL201685B1 (et)
PT (1) PT1257275E (et)
RS (1) RS50404B (et)
RU (1) RU2257207C2 (et)
SI (1) SI1257275T1 (et)
SK (1) SK284952B6 (et)
TW (1) TWI243677B (et)
UA (1) UA72783C2 (et)
WO (1) WO2001058450A2 (et)
ZA (1) ZA200205317B (et)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2804604B1 (fr) * 2000-02-09 2005-05-27 Sanofi Synthelabo Utilisation d'un antagoniste des recepteurs aux cannabinoides centraux pour la preparation de medicaments utiles pour faciliter l'arret de la consommation de tabac
US6462237B1 (en) * 2001-06-14 2002-10-08 Usv Limited Cyclodextrin stabilized pharmaceutical compositions of bupropion hydrochloride
US8129253B2 (en) 2001-08-13 2012-03-06 Finisar Corporation Providing current control over wafer borne semiconductor devices using trenches
EP1496838B1 (en) 2002-03-12 2010-11-03 Merck Sharp & Dohme Corp. Substituted amides
JP2005528366A (ja) 2002-03-26 2005-09-22 メルク　エンド　カムパニー　インコーポレーテッド カンナビノイド受容体モジュレータとしてのスピロ環式アミド
EP1492784A4 (en) 2002-03-28 2006-03-29 Merck & Co Inc SUBSTITUTED 2,3-DIPHENYLPYRIDINES
EP1499306A4 (en) 2002-04-12 2007-03-28 Merck & Co Inc BICYCLIC AMIDE
US6825209B2 (en) 2002-04-15 2004-11-30 Research Triangle Institute Compounds having unique CB1 receptor binding selectivity and methods for their production and use
ATE375349T1 (de) 2002-08-02 2007-10-15 Merck & Co Inc Substituierte furo(2,3-b)pyridin derivate
JP2006510597A (ja) 2002-09-27 2006-03-30 メルク　エンド　カムパニー　インコーポレーテッド 置換ピリミジン類
US7129239B2 (en) 2002-10-28 2006-10-31 Pfizer Inc. Purine compounds and uses thereof
US7247628B2 (en) 2002-12-12 2007-07-24 Pfizer, Inc. Cannabinoid receptor ligands and uses thereof
EP1575901B1 (en) 2002-12-19 2012-10-10 Merck Sharp & Dohme Corp. Substituted amides
US7329658B2 (en) 2003-02-06 2008-02-12 Pfizer Inc Cannabinoid receptor ligands and uses thereof
US7176210B2 (en) 2003-02-10 2007-02-13 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
US7145012B2 (en) 2003-04-23 2006-12-05 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
US7268133B2 (en) 2003-04-23 2007-09-11 Pfizer, Inc. Patent Department Cannabinoid receptor ligands and uses thereof
US20040224963A1 (en) * 2003-05-09 2004-11-11 Pfizer Inc Pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal
US20040224962A1 (en) * 2003-05-09 2004-11-11 Pfizer Inc Pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss
CA2526103A1 (en) * 2003-05-20 2004-12-29 Bob M. Ii Moore Cannabinoid derivatives, methods of making, and use thereof
US7232823B2 (en) 2003-06-09 2007-06-19 Pfizer, Inc. Cannabinoid receptor ligands and uses thereof
AU2004287849A1 (en) * 2003-10-30 2005-05-19 Merck Sharp & Dohme Corp. Aralkyl amines as cannabinoid receptor modulators
KR20070041717A (ko) 2004-07-12 2007-04-19 카딜라 핼쓰캐어 리미티드 카나비노이드 수용체 조절자인 트리시클릭 피라졸 유도체들
US20060025448A1 (en) 2004-07-22 2006-02-02 Cadila Healthcare Limited Hair growth stimulators
KR101351209B1 (ko) 2004-12-03 2014-02-06 머크 샤프 앤드 돔 코포레이션 Ｃｂ1 길항제로서 치환된 피페라진
MX2008009354A (es) * 2006-01-18 2008-09-30 Schering Corp Moduladores de receptores cannabinoides.
CN101062919B (zh) * 2006-04-26 2012-08-15 中国人民解放军军事医学科学院毒物药物研究所 4-甲基-1h-二芳基吡唑衍生物及其作为药物的用途
WO2007121687A1 (fr) * 2006-04-26 2007-11-01 Institute Of Pharmacology And Toxicology Academy Of Military Medical Sciences P.L.A. China Dérivés du 4-méthyl-1h-diaryl pyrazole et leur utilisation comme médicaments
US20070287734A1 (en) * 2006-06-09 2007-12-13 Auspex Pharmaceuticals, Inc. Preparation and utility of substituted pyrazole compounds with cannabinoid receptor activity
RU2477634C2 (ru) * 2006-06-16 2013-03-20 Теракос, Инк. Лечение психологических состояний с применением антагонистов m1-мускариновых рецепторов
KR101434334B1 (ko) * 2006-10-20 2014-08-28 아비에 비.브이. 화학 물질의 마이셀 나노입자
WO2008130616A2 (en) * 2007-04-19 2008-10-30 Schering Corporation Diaryl morpholines as cb1 modulators
CN101790521A (zh) * 2007-06-28 2010-07-28 英特维特国际股份有限公司 作为cb1拮抗剂的取代哌嗪
NZ582249A (en) * 2007-06-28 2012-06-29 Intervet Int Bv Substituted piperazines as cb1 antagonists
EP2095814A1 (de) * 2008-02-26 2009-09-02 Wolfgang J. Kox Medikamentengestützter Nikotinentzug
WO2010018856A1 (ja) * 2008-08-13 2010-02-18 持田製薬株式会社 カンナビノイド受容体関連疾患の予防／改善または治療剤
RU2533224C2 (ru) * 2010-07-21 2014-11-20 Мапикс Эс.Эй.Ар.Эл. Способ лечения зависимости от психоактивных веществ, алкоголизма и табакокурения и лекарственное средство для лечения зависимости от психоактивных веществ, алкоголизма и табакокурения
WO2013068371A1 (en) 2011-11-08 2013-05-16 Intervet International B.V. Soft chewable dosage form compositions of cannabinoid receptor type 1 (cb-1) antagonists
WO2014181357A1 (en) * 2013-05-09 2014-11-13 Council Of Scientific & Industrial Research Novel pyrazole derivatives with silicon incorporation
US20200035118A1 (en) 2018-07-27 2020-01-30 Joseph Pandolfino Methods and products to facilitate smokers switching to a tobacco heating product or e-cigarettes
US10897925B2 (en) 2018-07-27 2021-01-26 Joseph Pandolfino Articles and formulations for smoking products and vaporizers

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5780051A (en) * 1992-04-02 1998-07-14 Dynagen, Inc. Methods and articles of manufacture for nicotine cessation and monitoring nicotine use
FR2692575B1 (fr) * 1992-06-23 1995-06-30 Sanofi Elf Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
FR2713225B1 (fr) * 1993-12-02 1996-03-01 Sanofi Sa N-pipéridino-3-pyrazolecarboxamide substitué.
US5596106A (en) * 1994-07-15 1997-01-21 Eli Lilly And Company Cannabinoid receptor antagonists
FR2758723B1 (fr) 1997-01-28 1999-04-23 Sanofi Sa Utilisation des antagonistes des recepteurs aux cannabinoides centraux pour la preparation de medicaments
FR2765107B1 (fr) * 1997-06-26 2000-03-24 Sanofi Sa Utilisation d'un antagoniste specifique des recepteurs 5ht2 pour la preparation de medicaments utiles dans le traitement du syndrome d'apnee du sommeil
FR2789079B3 (fr) 1999-02-01 2001-03-02 Sanofi Synthelabo Derive d'acide pyrazolecarboxylique, sa preparation, les compositions pharmaceutiques en contenant
FR2804604B1 (fr) * 2000-02-09 2005-05-27 Sanofi Synthelabo Utilisation d'un antagoniste des recepteurs aux cannabinoides centraux pour la preparation de medicaments utiles pour faciliter l'arret de la consommation de tabac

Also Published As

Publication number Publication date
NO20023765D0 (no) 2002-08-08
JP2003522145A (ja) 2003-07-22
UA72783C2 (en) 2005-04-15
EP1257275A2 (fr) 2002-11-20
US20030087933A1 (en) 2003-05-08
NO20023765L (no) 2002-10-09
HUP0300237A2 (hu) 2003-07-28
SK284952B6 (sk) 2006-03-02
ZA200205317B (en) 2003-09-04
DE60109903D1 (de) 2005-05-12
MXPA02007766A (es) 2002-10-11
RU2257207C2 (ru) 2005-07-27
PT1257275E (pt) 2005-07-29
CA2397262C (en) 2007-09-11
HK1051140A1 (en) 2003-07-25
HUP0300237A3 (en) 2003-09-29
ES2240416T3 (es) 2005-10-16
FR2804604B1 (fr) 2005-05-27
YU59002A (sh) 2005-07-19
NZ519924A (en) 2005-01-28
FR2804604A1 (fr) 2001-08-10
US20050187253A1 (en) 2005-08-25
WO2001058450A2 (fr) 2001-08-16
AU3562001A (en) 2001-08-20
BG65856B1 (bg) 2010-03-31
ATE292467T1 (de) 2005-04-15
AU781827B2 (en) 2005-06-16
CN1250220C (zh) 2006-04-12
PL358221A1 (en) 2004-08-09
SK11292002A3 (sk) 2003-02-04
IL150710A0 (en) 2003-02-12
CZ296685B6 (cs) 2006-05-17
RU2002118309A (ru) 2004-02-20
TWI243677B (en) 2005-11-21
CZ20022698A3 (cs) 2002-11-13
BR0108126A (pt) 2003-01-28
US6930122B2 (en) 2005-08-16
AR028505A1 (es) 2003-05-14
RS50404B (sr) 2009-12-31
CA2397262A1 (en) 2001-08-16
SI1257275T1 (en) 2005-10-31
PL201685B1 (pl) 2009-04-30
CN1406128A (zh) 2003-03-26
DE60109903T2 (de) 2006-02-09
NO324521B1 (no) 2007-11-12
EP1257275B1 (fr) 2005-04-06
EE04836B1 (et) 2007-06-15
HU225328B1 (en) 2006-09-28
DK1257275T3 (da) 2005-08-08
IS6450A (is) 2002-06-28
BG110386A (en) 2009-09-30
BG106946A (bg) 2003-05-30
WO2001058450A3 (fr) 2002-04-25
JP2010018622A (ja) 2010-01-28

Similar Documents

Publication Publication Date Title
EE200200439A (et) Tsentraalsete kannabinoidiretseptorite antagonisti kasutamine ravimtoodete valmistamiseks, aitamaksloobuda tubakatarbimisest
MA27366A1 (fr) Nouveaux derives de thiophenylglycoside, methodes pour leur production, medicaments contenant lesdits composes et leur utilisation
MA26903A1 (fr) Production continue de granules pharmaceutiques
EE200300033A (et) Tsüklopentanoindoolid, nende kasutamine ravimi valmistamiseks ning neid sisaldav farmatseutiline kompositsioon
HUP0302167A3 (en) Quinoline derivatives as metabotropic glutamate receptor antagonists, pharmaceutical compositions containing them and process for producing them
IL163831A0 (en) Derivatives of aminoindazoles, method of preparation and intermediates of the method as drugs pharmaceutical compounds containing
MA28337A1 (fr) Derives de l'acide 7-phenylamino-4-quinolone-3-carboxylique, methodes pour leur production et leur utilisation en tant que medicaments
IS2448B (is) Pýrasólkarboxýlsýruafleiður, framleiðsla þeirra, lyfjasamsetningar sem innihalda þær
HUP0301742A3 (en) Colchinol derivatives as angiogenesis inhibitors, process for producing them, pharmaceutical compositions containing them and their use
HUP0301671A3 (en) 4-phenyl-pyridine derivatives as neurokinin-1 receptor antagonists, process for their preparation and their use
NO20032773D0 (no) Farmasöytisk preparat som omfatter pyrsazolo [4,3-d] pyrimidiner og antitrombotika, kalsiumantagonister, prostaglandiner ellerprostaglandinderivater
IS6811A (is) Lyfjafræðilegar samsetningar NMDA viðtakagerandefna
EE200300245A (et) Bensotiofeeni derivaadid, nende valmistamise meetod ja kasutamine
NO20015149L (no) Nytt farmasöytisk preparat
NO20014738L (no) Tolperisonholdig farmasöytisk preparat for oral administrering
WO2002030870A3 (de) Substituierte c-cyclohexylmethylamin-derivate
HK1126200A1 (en) Isoquinoline et benzo[h]isoquinoline derivatives, preparation and therapeutic use thereof as antagonists of histamine h3 receptor
WO2001049654A3 (de) Substituierte aminomethyl-phenyl-cyclohexanderivate
WO2001049651A3 (de) Aminomethyl-phenyl-cyclohexanonderivate
HUP0303127A3 (en) Novel lipoic acid heterocyclic or benzene derivatives, preparation and use thereof as medicines
HUP0300694A3 (en) Indole derivatives as mcp-1 receptor antagonists, their use, process for their preparation and pharmaceutical compositions containing them
NO20015104D0 (no) Nytt farmasöytisk preparat
MXPA02009210A (es) Modificacion amorfa de torasemida.
NO20044332L (no) Forbedret fremgangsmate for fremstilling av nevirapine
ITRM20000659A0 (it) Esteri dell'acido fenilbutirrico, procedimenti per la loro produzionee loro impiego terapeutico.

Legal Events

Date Code Title Description
HC1A Change of owner name
KB4A Valid patent at the end of a year

Effective date: 20071231

KB4A Valid patent at the end of a year

Effective date: 20081231

MM4A Lapsed by not paying the annual fees

Effective date: 20100207